Category: snoring and apnea

VirtuOx Launches Mobile Cardiac Telemetry Program 0

VirtuOx Launches Mobile Cardiac Telemetry Program

Home respiratory diagnostic provider VirtuOx has launched a new service: CardioCHECK, a way to diagnose cardiac arrhythmias in the patient’s home.

The VirtuOx CardioCHECK program allow prescribers to order mobile cardiac telemetry (MCT) at the same time as other VirtuOx services like overnight pulse oximetry for nocturnal hypoxemia or home sleep testing for obstructive sleep apnea.

Kyle Miko, founder and CMO for VirtuOx, says in a release, “Research has shown arrhythmias are common with patients who have comorbid conditions like sleep apnea and hypoxemia so now offering mobile cardiac telemetry was a natural progression for VirtuOx.”

Bill Bowden, DO, FACC, a VirtuOx medical directors says, “with access to this large amount of data, we have uncovered huge patient populations who have cardiac arrhythmias at night with severe bradycardia/tachycardia events who may benefit from an MCT.”

from Sleep Review http://www.sleepreviewmag.com/2019/03/virtuox-launches-mobile-cardiac-telemetry-program/…

Itamar Launches Next Generation WatchPAT Home Sleep Test 0

Itamar Launches Next Generation WatchPAT Home Sleep Test

Itamar Medical Ltd has launched the WatchPAT 300, the next generation of its WatchPAT system for home sleep apnea testing.

“[Sleep apnea] has significant health and economic implications, as half of all patients with cardiovascular disease are believed to suffer from sleep apnea and the total cost of unmanaged obstructive sleep apnea is $150 billion each year in the United States alone,” says Gilad Glick, president and CEO of Itamar Medical, in a release. “Addressing the challenge of efficiently and cost-effectively diagnosing the millions of patients with undiagnosed sleep apnea requires a simple, accurate, and scalable modality. We believe that WatchPAT 300—which demonstrates Itamar Medical’s continued commitment to innovation focused on meeting the needs of patients, health systems, payers, and physicians—can play a critical role in solving this challenge.”

WatchPAT 300 utilizes peripheral arterial tone and other signals to calculate various sleep metrics and to diagnose both obstructive and central sleep apnea.

WatchPAT 300 has three points of contact does not use a nasal canula or chest belts. It is based on the peripheral arterial tone signal (PAT) and uses

FDA Approves Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or OSA 0

FDA Approves Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or OSA

The US Food and Drug Administration (FDA) approved solriamfetol, which will be known be marketed by Jazz Pharmaceuticals as the brand name “Sunosi,”  to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

Sunosi is the first dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved to treat excessive daytime sleepiness in adults living with narcolepsy or OSA. Once-daily Sunosi is approved with doses of 75 mg and 150 mg for patients with narcolepsy and doses of 37.5 mg, 75 mg, and 150 mg for patients with OSA.

Sunosi is expected to be commercially available in the United States following the final scheduling decision by the US Drug Enforcement Administration (DEA), which is typically within 90 days of FDA approval.

“Excessive daytime sleepiness can negatively impact the daily lives of people living with narcolepsy or obstructive sleep apnea at work, at home, or in daily activities. With this approval, a new, daytime medicine that can provide sustained wakefulness throughout the day will be available for patients,” says Bruce Cozadd, chairman and CEO of

Jazz Pharmaceuticals: FDA Approves Sunosi for Excessive Daytime Sleepiness in Narcolepsy or OSA 0

Jazz Pharmaceuticals: FDA Approves Sunosi for Excessive Daytime Sleepiness in Narcolepsy or OSA

There’s a new option for patients who experience excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

Jazz Pharmaceuticals announced that the U.S. Food and Drug Administration approved Sunosi (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or OSA.

 

Once-daily Sunosi is approved with doses of 75 mg and 150 mg for patients with narcolepsy and doses of 37.5 mg, 75 mg, and 150 mg for patients with OSA. This medication is not indicated to treat the underlying airway obstruction in OSA.

Sunosi is expected to be commercially available in the U.S. following the final scheduling decision by the U.S. Drug Enforcement Administration (DEA), which is typically within 90 days of FDA approval.

“Excessive daytime sleepiness can negatively impact the daily lives of people living with narcolepsy or obstructive sleep apnea at work, at home or in daily activities. With this approval, a new, daytime medicine that can provide sustained wakefulness throughout the day will be available for patients,” said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. “The 

Is Your Sleep Apnea Machine Snitching to Your Insurer? 0

Is Your Sleep Apnea Machine Snitching to Your Insurer?

Device manufacturers aren’t covered by the Health Insurance Portability and Accountability Act (HIPAA) of 1996, reports Bloomberg Law.

“So, in most cases, when an individual hands over their health data to a device company, that company is not prohibited from disclosing that data to other entities. This gives device companies a lot of leeway in terms of what they can do with health information they obtain.”

from Sleep Review http://www.sleepreviewmag.com/2019/03/is-your-sleep-apnea-machine-snitching-to-your-insurer/…

Study Finds Significant Differences in How Various ASV Devices Treat Complex Sleep Apnea 0

Study Finds Significant Differences in How Various ASV Devices Treat Complex Sleep Apnea

Adaptive servo ventilation (ASV) is an effective treatment option for patients with complex sleep apnea, according to a Philips-sponsored study published in the American Journal of Respiratory and Critical Care Medicine. The study, Comparison of Physiological Performance of Four Adaptive Servo Ventilation Devices in Patients with Complex Sleep Apnea, compared the performance of 4 different ASV devices with different algorithms, including Philips DreamStation BiPAP autoSV (pictured), and the ASV device that was originally associated with greater mortality during a prior SERVE-HF trial published in 2015. The recent study revealed that certain physiological performances were quite different across the devices.

In the prior SERVE-HF trial, it was suggested that ASV therapy was harmful to central sleep apnea patients with heart failure, with limited information suggesting that some of the patients in the trial may have received excessive minute ventilation that may have increased patient mortality. This new Philips-funded randomized controlled study suggests the mechanisms underlying the adverse effects of ASV may be secondary to excessive ventilation due to device-based effect rather than a class-effect.

“The pursuit for scientific

The Dangers Snoring Women Face 0

The Dangers Snoring Women Face

Both men and women snore. Sure, it’s a bit of a turn off for some of the women out there but that’s reality. Everybody snores. It’s just that there are more men who snore.

There exist anatomical differences in the bodies of both women and men that cause men to take the lead. 4 out of every 10 men snore, in comparison to roughly 3 out of 10 women.

(Via: https://flo.health/menstrual-cycle/lifestyle/sleep/ways-to-prevent-snoring)

Here’s a good reason why men snore more than women.

Men are born with air channels that are narrower than women’s—and this causes unpleasant noise during night time. The narrower the air passage, the harder it is for the oxygen to flow during the normal breathing activity. Also, when air is forced through a narrow opening, the tissues surrounding it vibrate aggressively and snoring becomes louder as a result.

Statistically, men consume alcohol more often than females do; they are also more likely to consume it in excess. The tendency to smoke is more in men as compared to women, leaving them vulnerable to snoring as a side

Simple Actions by Healthcare Professionals Can Increase CPAP Adherence 0

Simple Actions by Healthcare Professionals Can Increase CPAP Adherence

A new study of the challenges and burdens faced by CPAP users reports that successful patient adherence to CPAP therapy requires new, personalized patterns of behavior incorporating physical, psychological, and cognitive adaptations. The study was conducted by research scientists from the Regenstrief Institute, Richard M. Roudebush Veterans Affairs Medical Center, and Indiana University – Purdue University Indianapolis (IUPUI).

“Telling patients they should exercise more or go on a diet is not a prescription for success, and neither is just handing them a CPAP machine with basic use instructions,” says Regenstrief Institute research scientist Edward Miech, EdD, who led the new study, in a release. “Simple actions, such as discussing the patient’s specific concerns during the crucial initial period, can successfully introduce CPAP treatment and could increase the likelihood of successful adherence.

“Unlike taking a pill, personal context—especially in the home situation—can make an enormous difference in terms of how well individual patients adapt to CPAP after receiving a diagnosis of obstructive sleep apnea. Given the irritating, ongoing challenges associated with CPAP adherence, helping patients adapt the treatment to the specifics

CVS Health Testing New HealthHUB Store Format 0

CVS Health Testing New HealthHUB Store Format

With the new format over 20% of the store is dedicated to health services, including new durable medical equipment (DME) and supplies and new product and service combinations for sleep apnea and diabetes care.

CVS Health is encouraged by its early results and customer response to HealthHUB®. The company says it will continue to pilot the Houston-based locations, with the goal of continuing to innovate and test to determine the right mix of products and services that can impact patient health while being scalable.

“We have a sense of urgency about the need to bring real change to health care,” said Kevin Hourican, EVP, CVS Health and president of CVS Pharmacy. “What’s clear to us is that it will take more than incremental steps to fix what is broken in the health care system. That’s why we’re excited about how the combination of CVS and Aetna can begin to establish an innovative health care model that will create an entirely new consumer experience and help people on their path to better health.”

Withings Launches Breathing Disturbance Detection for Sleep Tracking Mat, Plans to Add Sleep Apnea Detection by End of 2019 0

Withings Launches Breathing Disturbance Detection for Sleep Tracking Mat, Plans to Add Sleep Apnea Detection by End of 2019

Withings has added new capabilities to its sleep sensor mat, the Withings Sleep, that it says will track and provide detailed information about breathing disturbances experienced during the night. Available to all current Sleep owners after performing an app update, the new feature charts their breathing disturbances over time and provides educational content to help users recognize the signs of sleep apnea.

The new feature acts as a first step towards Withings’ strategy to introduce even more advanced sleep diagnostics including sleep apnea detection. Withings aims to add these capabilities by the end of 2019, subject to FDA and CE clearances.

According to the company, the new Withings Sleep breathing feature provides users with an early warning system to allow them to identify hard to diagnose potential issues and where appropriate, seek medical advice.

Breathing disturbances is a free upgrade for Withings Sleep and was developed and extensively tested by sleep physician Dr Pierre Escourrou within the Paris-Béclère hospital sleep lab using polysomnography (PSG) analysis.

Withings Sleep is a mat that fits under the mattress and after a onetime setup